Advertisement

Diabetic Kidney Disease

  • Ting Cai
  • Junwei YangEmail author
Chapter

Abstract

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) and is strongly associated with mortality in patients with diabetes. Persistent albuminuria is the hallmark of DKD, and some patients will finally develop ESRD with gradually decreased glomerular filtration rate (GFR) and increased serum creatinine concentration. Glomerular basement membrane thickening, mesangial expansion, mesangial matrix accumulation, Kimmelstiel–Wilson nodules, and tubulointerstitial fibrosis are typical pathological changes in DKD. Screening for DKD should begin at 5 years after the diagnosis of type 1 diabetes and at the diagnosis of type 2 diabetes, which should include measurement of urinary albumin-to-creatinine ratio and serum creatinine concentration, estimation of GFR, and ophthalmologic examination. The progression of DKD may be slowed by optimal therapeutic approaches, including lifestyle improvement, strict glycemic and blood pressure control, control of dyslipidemia, and renin–angiotensin–aldosterone system blockade. Patients who develop ESRD require renal replacement therapy.

References

  1. 1.
    IDF Diabetes Atlas. 8th ed. 2017.Google Scholar
  2. 2.
    Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–83.CrossRefGoogle Scholar
  3. 3.
    Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49(9):1399–408.CrossRefGoogle Scholar
  4. 4.
    Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–93.CrossRefGoogle Scholar
  5. 5.
    Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12(1):83–98.7.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mogensen C. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes. 1997;46(Supplement 2):S104–S11.CrossRefGoogle Scholar
  7. 7.
    Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(10):1064–70.CrossRefGoogle Scholar
  8. 8.
    Musso C, Javor E, Cochran E, Balow JE, Gorden P. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin Am Soc Nephrol. 2006;1(4):616–22.CrossRefGoogle Scholar
  9. 9.
    KDOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.Google Scholar
  10. 10.
    Redon J. Measurement of microalbuminuria—what the nephrologist should know. Nephrol Dial Transplant. 2006;21(3):573–6.CrossRefGoogle Scholar
  11. 11.
    Wolf G, Muller N, Mandecka A, Muller UA. Association of diabetic retinopathy and renal function in patients with types 1 and 2 diabetes mellitus. Clin Nephrol. 2007;68(2):81–6.CrossRefGoogle Scholar
  12. 12.
    The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47(6):1703–20.CrossRefGoogle Scholar
  13. 13.
    Group DER, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365(25):2366–76.CrossRefGoogle Scholar
  14. 14.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRefGoogle Scholar
  15. 15.
    American Diabetes Association. Clinical Practice Recommendations 2001. Diabetes Care. 2001;24(Suppl 1):S1–133.Google Scholar
  16. 16.
    KDIGO. 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.CrossRefGoogle Scholar
  17. 17.
    Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11(3):309–17.CrossRefGoogle Scholar
  18. 18.
    Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.CrossRefGoogle Scholar
  19. 19.
    Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–37.CrossRefGoogle Scholar
  20. 20.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456–62.CrossRefGoogle Scholar
  21. 21.
    Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156(3):286–9.CrossRefGoogle Scholar
  22. 22.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.CrossRefGoogle Scholar
  23. 23.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–6.CrossRefGoogle Scholar
  24. 24.
    Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant. 2002;17(1):112–7.CrossRefGoogle Scholar
  25. 25.
    Winkelmayer WC, Glynn RJ, Mittleman MA, Levin R, Pliskin JS, Avorn J. Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach. J Am Soc Nephrol. 2002;13(9):2353–62.CrossRefGoogle Scholar
  26. 26.
    Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.CrossRefGoogle Scholar
  27. 27.
    Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365(4):327–36.CrossRefGoogle Scholar
  28. 28.
    De Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492–503.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Nanjing Medical UniversityNanjingChina
  2. 2.Centre for Kidney DiseaseSecond Affiliated Hospital, Nanjing Medical UniversityNanjingChina

Personalised recommendations